Catalyst Intel Subscribe

Trial results

$DMAC — DM199

DiaMedica Therapeutics Inc. (DMAC) DM199: trial results in Acute ischemic stroke, 2027.

Research by Catalyst Intel

The catalyst

"ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial Surpasses 200-Participant Enrollment Threshold; Interim Analysis Expected Q1 2027"

— DiaMedica Therapeutics, 8-K filed 2026-11-12 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id
DMAC-DM199-2026
Company
DiaMedica Therapeutics Inc.
Kind
Trial results
Indication
Acute ischemic stroke
Window
2027-01-01 – 2027-03-31
Status
dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.